Our Approach

R&D and Delivery

Awakn’s unique approach combines two areas: the Research and Development of new therapeutics (drugs and therapies to be used in combination), and the delivery of those therapeutics through our specialist clinics.

Our Research & Development arm is engaged in pre-clinical and clinical research to develop therapeutics to treat addiction. We have drug discovery and clinical research programmes active across substance and behavioural additions.

Our delivery arm deliver these proven therapeutics through our specialised clinics in the UK and Europe. The clinics will generate real world data and evidence that supports our R&D activities. We will establish licensing partnerships to deliver these therapeutics globally, starting with the US and Canada in 2022.

Revenue generated from the clinics and licensing partnerships will fund our ongoing research. Awakn is unique in the biotechnology industry in that we have both a deep commercialisable IP portfolio, and near-term scalable revenue streams.

How psychedelic-assisted therapy works

Existing addiction medicines target drug receptors in the brain, to reduce symptoms such as cravings. These have low long-term success rates for substance addiction, and offer no solution to behavioural addiction.

Our approach is different, delivering profound and long lasting changes over a single course of treatment.

Addiction – like anxiety, depression, and PTSD – is based on patterns of behaviour established in the brain, usually in response to trauma.

Our psychedelics disrupt the brain circuits that underlie these unhelpful patterns. They weaken neural connections linked to harmful thought patterns, opening the door for clients to rewrite constructive alternatives. By focusing on circuit mechanisms, not receptors, our approach has potential to work in behavioural addictions such as gambling, and for mental health conditions.

Through inducing these conditions that allow relearning of emotional responses, our psychotherapists can engage clients with root causes of their addiction.

This is an entirely new paradigm for mental health, where we are moving from palliative care towards permanent cure. We believe this is the biggest change to psychiatry in 100 years.

Read more about our Research and Clinical Trials and How our clinics will operate.

Sign Up for Newsletter


301-217 Queen St. W, Toronto, ON, M5V 0R2, Canada

1 Regent Street, Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy

Back to top Arrow